Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The company reported net revenue of SEK 13.5 million for the full year 2025
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Former Wavemaker executive to lead media strategy and digital transformation agenda
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Subscribe To Our Newsletter & Stay Updated
